<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interleukin (IL)-1 plays an important role not only in the mediation of <z:mp ids='MP_0001845'>inflammation</z:mp> but also in the destruction of cartilage and bone </plain></SENT>
<SENT sid="1" pm="."><plain>Together with TNF-alpha it is one of the most important cytokines in the pathogenesis of <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) and juvenile idiopathic <z:hpo ids='HP_0001369'>arthritis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The first IL-1 antagonist to be approved for RA was Anakinra, an IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Anakinra appears to be less effective for RA than TNF blockers </plain></SENT>
<SENT sid="4" pm="."><plain>Hence, Anakinra is rarely used for the treatment of RA, but more for the treatment of IL-1-mediated diseases such as autoinflammatory syndromes, <z:hpo ids='HP_0003581'>adult-onset</z:hpo> <z:e sem="disease" ids="C0087031" disease_type="Disease or Syndrome" abbrv="">Still's disease</z:e> and systemic <z:hpo ids='HP_0003674'>onset</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Two newer IL-1 antagonists have recently been approved for the treatment of CAPS (cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndromes</z:e>): Canakinumab, a fully human IL-1beta antibody, and rilonacept, a fusion protein consisting of the ligand-binding domain of the IL-1 receptor and the IL-1-receptor accessory protein, bound to human IgG1 </plain></SENT>
<SENT sid="6" pm="."><plain>For RA, there is only one proof-of-concept study to date with canakinumab </plain></SENT>
<SENT sid="7" pm="."><plain>There are no prospective data for the treatment of patients with RA who did not respond to or tolerate TNF <z:chebi fb="68" ids="48706">antagonists</z:chebi>; in a retrospective analysis, only 8% of anti-TNF pretreated patients achieved an ACR 20 response </plain></SENT>
</text></document>